Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
There is a complex interplay of factors that gives shape to the critical healthcare segment in hyperglycemia treatment market dynamics. The rising global prevalence of diabetes necessitates a well-established market for effective treatments of hyperglycemia, which is high blood sugar levels. The primary factor behind the market growth rate is the escalation in diabetes mellitus incidence (both type 1 and type 2). As our lifestyle becomes inactive and diet pattern undergoes drastic changes, the number of those suffering from hyperglycemia continues to increase, leading pharmaceutical firms to invest in extensive research and development for more innovative treatment alternatives.
Apart from increasing cases of hyperglycemia, technological advancements and an enhanced understanding on molecular mechanisms have contributed significantly towards this phenomenon. Hyperglycemic therapy’s field has shifted with brand new curative approaches such as insulin analogs, oral hypoglycemic agents and advanced glucose monitoring tools. Such advances not only increase efficacy but also improve patient adherence hence fostering growth in market rates. This dynamic nature can be underlined by continued search for improved drug formulations including combination therapies and long-acting insulin in hyperglycemia treatment.
The government initiatives as well as health care policies play an important role in shaping market dynamics. Governments all over the world are focusing on preventive measures, early diagnosis and affordable treatments due to the fact that diabetes has become a global health concern. Consequently there has been a favorable regulatory environment that encourages pharmaceutical companies to invest in the development of hyperglycemia drugs. Additionally, it promotes early diagnosis through patient education alongside awareness programs thus stimulating the growth of hyperglycemia markets.
Intense competition among many pharmaceutical companies defines competitive forces within this particular industry sector for treating diabetes patients with high blood sugar levels or any other kind of medical condition connected with an elevated blood sugar level like hypoglycemia or diabetic ketoacidosis (DKA). While innovative therapeutic solutions drive competition, it also comes from strategic alliances, mergers and acquisitions. They seek to extend their product portfolios by leveraging synergies so as to achieve a competitive advantage in such quickly changing settings. This is accompanied by the introduction of biosimilars and generic versions of existing drugs thus intensifying competition implying that patients have cheaper alternatives and the market grows.
Market dynamics are also shaped by the patient’s preferences and demands. In the era of personalized medicine, patients increasingly look for treatments adapted to their individual needs. Pharmaceutical companies are therefore encouraged towards targeted therapies as well as precision medicine approaches for hyperglycemia treatment. Such factors also influence overall market growth through development of user-friendly insulin delivery devices or convenient oral medications for diabetes mellitus.
However, there continue to be challenges within the market for hyperglycemia treatment including high cost advanced therapy drugs, reimbursement issues associated with insurance coverage by health plans and continuous medical education (CME) regarding new treatment modalities needing healthcare professionals’ understanding. Overcoming these challenges calls for collaboration between health providers, regulatory bodies as well as industry stakeholders towards realizing affordable access to effective interventions against hyperglycemia.”
Hyperglycemia Treatment Market Highlights:
Hyperglycemia Treatment Market Scenario
The Hyperglycemia Treatment Market is projected to reach USD 1,258.9 Million by 2030 at 10.40% CAGR during the forecast period 2022-2030. Hyperglycemia is an excess of glucose in the bloodstream, and is often associated with diabetes mellitus. It occurs when the body does not have enough insulin to control the sugar level or unable to produce the insulin. Furthermore, hyperglycemia if remains untreated may cause serious complications such as nerve damage or neuropathy, kidney damage, kidney failure, cardiovascular disease, eye disease, and skin problems such as bacterial and fungal infections. The major signs of hyperglycemia are polydipsia (a great thirst), polyuria (a need to urinate often), and a dry mouth.
Increasing prevalence of diabetes, and growing investment in biotechnology and pharmaceutical industries, and rising need for the better treatment methods drive the growth of the Hyperglycemia Treatment Market.
According to the WHO, the global prevalence of diabetes among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014. Where as in 2015, 1.6 million deaths were caused due to diabetes. Another, 2.2 million deaths were attributed to high blood glucose level in 2012.
According to the WHO estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies across the globe. This is higher than the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.
Moreover, increasing awareness about diabetes care and management, and advancing technology in medical devices are adding fuel to the growth of the market. Furthermore, increasing prevalence of obesity and consumption of unhealthy diet also drive Hyperglycemia Treatment Market growth.
However, availability of expensive treatment and poor reimbursement policy are some of the factors, which may slow the Hyperglycemia Treatment Market growth during the forecast period.
Figure: Hyperglycemia Treatment Market, By Region Market Share, 2016 (%) 
Sources: Annual reports, Press release, White paper, Company presentation
Segmentations
The hyperglycemia treatment market is segmented on the basis of treatment, mode of administration, and end user.
On the basis of treatment, it is segmented into fluid replacement, electrolyte replacement, insulin therapy, and drugs. The drugs segment is further segmented into sulfonylureas, biguanides, thiazolidinediones, and others.
On the basis of mode of administration, it is segmented into topical, oral, and others.
On the basis of end user, the market is segmented into hospitals & clinics, retail pharmacy, and others
Regional Analysis
The Americas dominates the hyperglycemia treatment market owing to well-developed technology, increasing patient with diabetes, increasing prevalence of neurological disorders, increasing patient population of kidney failure caused by severe hyperglycemia, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.
Europe holds the second position in the hyperglycemia treatment market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, countries like Germany and France are increasing investment in the healthcare domain.
Asia Pacific is the fastest growing hyperglycemia treatment market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods in countries like India and South Korea is likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare projected to lead to the use of advanced equipment, which, in turn, will increase the market growth of the hyperglycemia treatment in the region.
On the other hand, the Middle East & Africa holds the least share of the market due to limited availability of medical facilities, less availability of funds, and poor political conditions in Africa.
Key Players
Some of key the players in the market are Novo Nordisk A/S, Merck & Company Inc., Medtronic, Johnson & Johnson Services, Inc. , Teva Pharmaceuticals Ltd., Eli Lilly and Company, Sanofi S.A., Home Diagnostics, Bayer AG, Bristol-Myers Squibb., and Abbott.
Research Methodology 
Sources: Annual reports, Press release, White paper, and Company presentation
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
